Having trouble accessing articles? Reset your cache.

Iressa gefitinib regulatory update

The U.K.'s NICE issued guidance recommending AstraZeneca's Iressa gefitinib for first-line

Read the full 112 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE